Advisors Preferred’s AstraZeneca AZN Stock Holding History

Advisors Preferred’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,112	Closed	-$356K	–	238
2025 Q3	$356K	Buy	+2,112	New	+$320K	0.05%	153
2024 Q1	–	Sell	-4,040	Closed	-$553K	–	175
2023 Q4	$553K	Buy	+4,040	New	+$525K	0.09%	94
2014 Q4	–	Sell	-1,270	Closed	-$90.7K	–	275
2014 Q3	$90.7K	Buy	1,270 +1,110	+694%	+$81.2K	0.06%	101
2014 Q2	$11.9K	Buy	+160	New	+$11.6K	0.01%	269
2014 Q1	–	Sell	-111	Closed	-$6K	–	346
2013 Q4	$6K	Buy	+111	New	+$6.03K	﹤0.01%	340

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Advisors Preferred's AZN Position: Q4 2025 in Review

Advisors Preferred sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 2,112 shares — an estimated $356K sold.

Advisors Preferred first reported a position in AZN in Q4 2013 and held it in 5 quarters. The position peaked at $553K in Q4 2023. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

Advisors Preferred reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
Advisors Preferred sold 2,112 AstraZeneca shares in Q4 2025, an estimated $356K.
Advisors Preferred first reported a position in AstraZeneca in Q4 2013 and held it in 5 quarters.
Advisors Preferred's AstraZeneca position peaked at $553K in Q4 2023.
1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Advisors Preferred's 13F filing for Q4 2025, filed 2 Feb 2026.